9-PAHSA Prevents Mitochondrial Dysfunction and Increases the Viability of Steatotic Hepatocytes
Authors:
- Adriana R. Schultz MoreiraAdriana R. Schultz Moreira
- Sabrina RüschenbaumSRSabrina Rüschenbaum
- Stefan SchefczykSSStefan Schefczyk
- Ulrike Hendgen-CottaUHUlrike Hendgen-Cotta
- Tienush RassafTienush Rassaf
- Ruth BroeringRBRuth Broering
- Matthias Hardtke-WolenskiMatthias Hardtke-Wolenski
- Laura Elisa Buitrago-MolinaLBLaura Elisa Buitrago-Molina
Open Access
- 5 November 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (21) , 8279
Abstract
Nonalcoholic fatty liver disease (NAFLD) is quickly becoming the most common liver disease worldwide. Within the NAFLD spectrum, patients with nonalcoholic steatohepatitis (NASH) are at the highest risk of developing cirrhosis and disease progression to hepatocellular carcinoma. To date, therapeutic options for NASH patients have been ineffective, and therefore, new options are urgently needed. Hence, a model system to develop new therapeutic interventions is needed. Here, we introduce two new in vitro models of steatosis induction in HepG2 cells and primary murine hepatocytes. We used a recently discovered novel class of bioactive anti-inflammatory lipids called branched fatty acid esters of hydroxyl fatty acids. Among these bioactive lipids, palmitic-acid-9-hydroxy-stearic-acid (9-PAHSA) is the most promising as a representative nondrug therapy based on dietary supplements or nutritional modifications. In this study, we show a therapeutic effect of 9-PAHSA on lipotoxicity in steatotic primary hepatocytes and HepG2 cells. This could be shown be increased viability and decreased steatosis. Furthermore, we could demonstrate a preventive effect in HepG2 cells. The outcome of 9-PAHSA administration is both preventative and therapeutically effective for hepatocytes with limited damage. In conclusion, bioactive lipids like 9-PAHSA offer new hope for prevention or treatment in patients with fatty liver and steatosis.Keywords
This publication has 23 references indexed in Scilit:
- Branched Fatty Acid Esters of Hydroxy Fatty Acids (FAHFAs) Protect against Colitis by Regulating Gut Innate and Adaptive Immune ResponsesJournal of Biological Chemistry, 2016
- Pathogenesis of nonalcoholic steatohepatitisCellular and Molecular Life Sciences, 2016
- S2k-Leitlinie nicht alkoholische FettlebererkrankungenZeitschrift für Gastroenterologie, 2015
- Discovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-inflammatory EffectsCell, 2014
- Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma developmentWorld Journal of Gastroenterology, 2014
- Epidemiology and Natural History of Non-Alcoholic SteatohepatitisClinics in Liver Disease, 2009
- Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevanceNature Clinical Practice Endocrinology & Metabolism, 2006
- Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitisHepatology, 2003
- Defective Hepatic Mitochondrial Respiratory Chain in Patients With Nonalcoholic SteatohepatitisHepatology, 2003
- Too much of a good thing? Toxic effects of vitamin and mineral supplements.2003